Abstract 278P
Background
Radical chemoradiation (CTRT) is the standard of care in locally advanced head and neck cancer (LAHNC). For mitigating the normal tissue toxicity, many techniques have been explored and utilized, including IMRT and adaptive radiotherapy (ART). Significant anatomical variations occur during CTRT due to weight loss and tumor and normal tissue changes. In the present study, serial changes in parotid volumes were assessed with weekly scans along with dosimetric correlation.
Methods
This prospective, single-institutional study, included 12 patients with LA HNC receiving CTRT. All underwent CT simulation (CT sim) followed by weekly rescans from week 1 to 6. Target volumes and organs at risk, including right & left parotids (RP & LP) were recontoured in all rescans after fusion with the CT sim. Dose overlay was done in each rescan to generate a hybrid plan to study corresponding dosimetric variations. Volume changes in parotids were reported as percentage change from the baseline.
Results
In CT sim, right parotid volumes (RPV) ranged from 15.7 - 44.2 cc (mean - 24.1 SD – 7.9) and left parotid volume (LPV) from 12.2 - 47.1 cm3 (mean 22.8, SD -9.9). Mean % reduction in RPV in week 1, 2, 3, 4, 5 and 6 were 14.2% (p=0.003), 17.1% (p=0.007), 21.8% (p < 0.001), 25.6% (p < 0.001), 30% (p < 0.001), 32.1% (p < 0.001) respectively. Mean % reduction in LPV in week 1, 2, 3, 4, 5 and 6 were 8.9% (p=0.016), 14.5% (p=0.012), 17.7% (p=0.001), 20.1% (p=0.002), 24.9% (p < 0.001), 28.9% (p < 0.001) respectively. LP D mean showed a significant increase in week 3 (4.6% from baseline, p=0.019) and week 6 (7.6% from baseline, p=0.034). Both parotids showed a significant reduction in V26 Gy with 12.3%, 15.1%, 18.9%, 22.9%, 25.7%, 27.0%, respectively, from week 1 to 6 in RP and 7.3%, 15.7%, 13.8%, 16.8%, 20.8%, 24.1%, respectively, in LP.
Conclusions
Parotid volume shrinkage started from the 1st week. At the end of CTRT, there was 30-32% reduction in volume. V26 Gy of both parotids showed significant reduction during CTRT. Studies focusing on parotid volume changes shows wide variations in volume reduction ranging from 13% to 50% at the end of treatment. These parotid volume changes during RT need to be incorporated while doing ART in LAHNC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Uttarakhand.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
298P - Abandonment of treatment in teenagers and young adults with cancer: A multi institutional survey
Presenter: B S Ankit
Session: e-Poster Display Session
304P - Identification of nine lncRNAs signature for predicting survival benefit of melanoma patients treated with immune checkpoint inhibitors
Presenter: Jian-Guo Zhou
Session: e-Poster Display Session
305P - Novel co-occurring genomic alterations associated with prediction and prognosis in lung adenocarcinoma
Presenter: Xin Zhao
Session: e-Poster Display Session
306P - Detection of anaplastic lymphoma kinase (ALK) mutations using circulating tumour DNA (ctDNA) in advanced non-squamous non-small cell lung cancer (non-Sq-NSCLC) in Asia
Presenter: Kirsty Lee
Session: e-Poster Display Session
307P - Development of circulating free DNA methylation markers for thyroid nodule diagnostics
Presenter: Shuibing Hong
Session: e-Poster Display Session
308P - The genomic landscape of non-small cell lung cancer (NSCLC) in East Asia using circulating tumour DNA (ctDNA) in clinical practice
Presenter: Byoung Cho
Session: e-Poster Display Session
309P - Improved diagnostic accuracy in MRI breast lesions using a classification system and multilayer perceptron neural network
Presenter: Venkata Pradeep Babu Koyyala
Session: e-Poster Display Session
310P - Genomic biomarker detection in East Asian clinical practice using circulating tumour DNA (ctDNA) from patients with gastrointestinal (GI) tract cancers
Presenter: Sadakatsu Ikeda
Session: e-Poster Display Session
311P - Effect of chemotherapy on fatty liver occurrence in breast and gastrointestinal cancer patients
Presenter: Seyed Alireza Javadinia
Session: e-Poster Display Session
312P - Identification of neoantigen-specific T cell response and anti-tumour immunity in pancreatic cancer
Presenter: Xiaoxiao Du
Session: e-Poster Display Session